{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T07:54:18Z","timestamp":1780559658390,"version":"3.54.1"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T00:00:00Z","timestamp":1516320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0191593","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T19:58:19Z","timestamp":1516391899000},"page":"e0191593","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5484-2030","authenticated-orcid":true,"given":"Caterina","family":"Peraldo-Neia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Cavalloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Fenocchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Cagnazzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Gammaitoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cereda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guglielmo","family":"Nasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"Satolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Aprile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Reni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Avallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosella","family":"Spadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Venesio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Doglioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo","family":"Frattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Aglietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,1,19]]},"reference":[{"issue":"13","key":"ref1","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1200\/JCO.2008.18.4408","article-title":"Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status","volume":"27","author":"G Goss","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1185\/03007995.2014.978448","article-title":"Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: a meta-analysis of 17 phase III randomized controlled trials","volume":"31","author":"WX Qi","year":"2015","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.lungcan.2014.03.026","article-title":"Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials","volume":"85","author":"N Zhao","year":"2014","journal-title":"Lung Cancer"},{"issue":"6","key":"ref4","article-title":"Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival","volume":"109","author":"CK Lee","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"ref5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1751-2980.2009.00393.x","article-title":"Meta-analysis: the efficacy and safety of monoclonal antibody targeted to epidermal growth factor receptor in the treatment of patients with metastatic colorectal cancer","volume":"10","author":"F Nie","year":"2009","journal-title":"J Dig Dis"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"e56205","DOI":"10.1371\/journal.pone.0056205","article-title":"EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis","volume":"8","author":"Z Jiang","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"RG Amado","year":"2008","journal-title":"J Clin Oncol"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3747\/co.20.1600","article-title":"Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer","volume":"20","author":"H Kennecke","year":"2013","journal-title":"Curr Oncol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1186\/1471-2407-10-631","article-title":"Targeting EGFR\/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas","volume":"10","author":"Y Pignochino","year":"2010","journal-title":"BMC Cancer"},{"issue":"12","key":"ref10","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S1470-2045(10)70247-3","article-title":"Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study","volume":"11","author":"B Gruenberger","year":"2010","journal-title":"Lancet Oncol"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(11)70301-1","article-title":"Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study","volume":"13","author":"J Lee","year":"2012","journal-title":"Lancet Oncol"},{"key":"ref12","article-title":"Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study)","author":"F Leone","year":"2015","journal-title":"Cancer"},{"issue":"7404","key":"ref13","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature11219","article-title":"The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers","volume":"486","author":"LA Diaz","year":"2012","journal-title":"Nature"},{"issue":"8","key":"ref14","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","article-title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis","volume":"11","author":"W De Roock","year":"2010","journal-title":"Lancet Oncol"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/ijc.30507","article-title":"EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS\/BRAF\/PIK3CA wild type metastatic colorectal cancer","volume":"140","author":"A \u00c5lgars","year":"2017","journal-title":"Int J Cancer"},{"issue":"9","key":"ref16","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/1078-0432.CCR-14-2821","article-title":"Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer","volume":"21","author":"S Arena","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1245\/s10434-007-9667-2","article-title":"Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number","volume":"15","author":"A Italiano","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/path.1779","article-title":"Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers","volume":"206","author":"K Nakazawa","year":"2005","journal-title":"J Pathol"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3892\/or.2014.3261","article-title":"Characterization of EGFR family gene aberrations in cholangiocarcinoma","volume":"32","author":"X Yang","year":"2014","journal-title":"Oncol Rep"},{"issue":"6","key":"ref20","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1158\/1078-0432.CCR-05-1692","article-title":"Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma","volume":"12","author":"F Leone","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"8","key":"ref21","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/sj.bjc.6604009","article-title":"PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients","volume":"97","author":"M Frattini","year":"2007","journal-title":"Br J Cancer"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1093\/annonc\/mdt416","article-title":"A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma","volume":"24","author":"DP Sohal","year":"2013","journal-title":"Ann Oncol"},{"issue":"5","key":"ref23","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1093\/annonc\/mdv035","article-title":"A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer","volume":"26","author":"JS Chen","year":"2015","journal-title":"Ann Oncol"},{"issue":"8","key":"ref24","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S1470-2045(14)70212-8","article-title":"Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial","volume":"15","author":"D Malka","year":"2014","journal-title":"Lancet Oncol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1471-2350-12-144","article-title":"The human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domain","volume":"12","author":"B Metzger","year":"2011","journal-title":"BMC Med Genet"},{"issue":"5","key":"ref26","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00428-014-1566-x","article-title":"Mutation status of somatic EGFR and KRAS genes in Chinese patients with prostate cancer (PCa)","volume":"464","author":"M Fu","year":"2014","journal-title":"Virchows Arch"},{"issue":"4","key":"ref27","first-page":"683","article-title":"Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study","volume":"22","author":"L Boldrini","year":"2009","journal-title":"Oncol Rep"},{"issue":"5","key":"ref28","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00408-013-9482-4","article-title":"Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18\u201321 sequencing results of 753 patients and subsequent clinical outcomes","volume":"191","author":"M Locatelli-Sanchez","year":"2013","journal-title":"Lung"},{"issue":"4","key":"ref29","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1097\/JTO.0b013e318169e341","article-title":"Long-lasting complete remission with tyrosine kinase inhibitor in bronchioloalveolar carcinoma with a so far unknown EGFR mutation","volume":"3","author":"V Ludovini","year":"2008","journal-title":"J Thorac Oncol"},{"key":"ref30","article-title":"Assessment of EGFR and ERBB2 (HER2) in Gastric and Gastroesophageal Carcinomas: EGFR Amplification is Associated With a Worse Prognosis in Early Stage and Well to Moderately Differentiated Carcinoma","author":"JB Liao","year":"2016","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"9","key":"ref31","doi-asserted-by":"crossref","first-page":"11645","DOI":"10.1007\/s13277-016-5140-9","article-title":"Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer","volume":"37","author":"J Yang","year":"2016","journal-title":"Tumour Biol"},{"issue":"35","key":"ref32","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1200\/JCO.2008.21.6796","article-title":"Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer","volume":"27","author":"P Laurent-Puig","year":"2009","journal-title":"J Clin Oncol"},{"issue":"36","key":"ref33","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.3748\/wjg.15.4511","article-title":"EGFR and HER2 expression in advanced biliary tract cancer","volume":"15","author":"J Harder","year":"2009","journal-title":"World J Gastroenterol"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/sj.bjc.6604129","article-title":"Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma","volume":"98","author":"D Yoshikawa","year":"2008","journal-title":"Br J Cancer"},{"issue":"33","key":"ref35","doi-asserted-by":"crossref","first-page":"e4584","DOI":"10.1097\/MD.0000000000004584","article-title":"Chemotherapy for advanced biliary tract carcinoma: A meta-analysis of randomized controlled trials","volume":"95","author":"L Chen","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"ref36","article-title":"A molecularly annotated model of patient-derived colon cancer stem-like cells to assess genetic and non-genetic mechanisms of resistance to anti-EGFR therapy","author":"P Luraghi","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"3","key":"ref37","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/1541-7786.MCR-11-0531","article-title":"In situ analysis of mutant EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and differential response to anti-EGFR targeted therapy","volume":"10","author":"AS Gajadhar","year":"2012","journal-title":"Mol Cancer Res"},{"issue":"11","key":"ref38","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/bjc.2011.161","article-title":"Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients","volume":"104","author":"M Scartozzi","year":"2011","journal-title":"Br J Cancer"},{"issue":"5","key":"ref39","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jhep.2004.07.016","article-title":"Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells","volume":"41","author":"JH Yoon","year":"2004","journal-title":"J Hepatol"},{"issue":"2","key":"ref40","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/annonc\/mdt540","article-title":"Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials","volume":"25","author":"JW Valle","year":"2014","journal-title":"Ann Oncol"},{"issue":"30","key":"ref41","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1200\/JCO.2010.29.3605","article-title":"Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study","volume":"28","author":"A Sharma","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"ref42","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","article-title":"Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial","volume":"16","author":"JW Valle","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"ref43","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/annonc\/mdu576","article-title":"A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study","volume":"26","author":"A Santoro","year":"2015","journal-title":"Ann Oncol"},{"issue":"1","key":"ref44","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.tranon.2014.12.003","article-title":"Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer","volume":"8","author":"ST Kim","year":"2015","journal-title":"Transl Oncol"},{"issue":"5","key":"ref45","doi-asserted-by":"crossref","first-page":"797","DOI":"10.21037\/jgo.2016.09.01","article-title":"Molecular profiling of biliary tract cancer: a target rich disease","volume":"7","author":"A Jain","year":"2016","journal-title":"J Gastrointest Oncol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0191593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,24]],"date-time":"2018-10-24T00:38:24Z","timestamp":1540341504000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0191593"}},"subtitle":[],"editor":[{"given":"John","family":"Souglakos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,1,19]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,1,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0191593","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,19]]}}}